PARP1 and neoplasm: Therefore, we argue that the addition of a PARP inhibitor to chemo-RIT creates more necrotic tumour cell targets for DAB4 binding and further increases tumour shrinkage, which together enhance the potency of La-directed and volume-adapted RIT.